KIMBERLEY DONALD: Open Payments
NPI 1245606946 · MILAN, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,869 in 70 payments from 16 companies in 2025. Trend: 2023 $737 · 2024 $1,439 · 2025 $1,869
Food & beverage: $1,870
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $934 |
| Ipsen Biopharmaceuticals, Inc | 4 | $182 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $138 |
| Novo Nordisk Inc | 1 | $124 |
| Celltrion USA Inc. | 2 | $100 |
| Gilead Sciences, Inc. | 2 | $91 |
| Janssen Biotech, Inc. | 3 | $64 |
| Madrigal Pharmaceuticals | 1 | $47 |
| Lilly USA, LLC | 2 | $37 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
Products named: SKYRIZI, RINVOQ, IQIRVO, CREON, Wegovy, LINZESS, ZYMFENTRA, Epclusa.
Industry payments across IL — which companies pay providers there.
